XBiotech Inc
XBIT
Company Profile
Business description
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.
Contact
5217 Winnebago Lane
AustinTX78744
USAT: +1 512 386-2900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
90
Stocks News & Analysis
stocks
Ask the analyst: Are Qantas shares a value trap?
Qantas’ pandemic woes seem a distant memory. But could the party end sooner than investors think?
stocks
Palantir earnings: Blockbuster growth amid high expectations
We raise our fair value estimate off the back of earnings.
stocks
ResMed earnings: Solid showing from ASX healthcare winner
Strong demand growth and improved profit margins lead to a strong result from the sleep apnea device firm.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,111.10 | 82.30 | 0.91% |
| CAC 40 | 7,621.04 | 10.97 | -0.14% |
| DAX 40 | 23,846.07 | 88.38 | 0.37% |
| Dow JONES (US) | 44,111.74 | 61.90 | -0.14% |
| FTSE 100 | 9,142.73 | 14.43 | 0.16% |
| HKSE | 24,915.86 | 13.33 | 0.05% |
| NASDAQ | 20,916.55 | 137.03 | -0.65% |
| Nikkei 225 | 40,794.86 | 245.32 | 0.60% |
| NZX 50 Index | 12,880.16 | 3.12 | 0.02% |
| S&P 500 | 6,299.19 | 30.75 | -0.49% |
| S&P/ASX 200 | 8,843.70 | 73.30 | 0.84% |
| SSE Composite Index | 3,631.93 | 14.33 | 0.40% |